HMGCR and gastroesophageal reflux disease: Also, lipase inhibitors (Padjusted = 6.08 × 10−3) and the statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) pathway (Padjusted = 3.99 × 10−2) were significantly enriched for AD and GERD (Supplementary Data 27), suggesting mechanisms of these medications may find therapeutic application in AD and GIT disorders.